Why invest in Hofseth BioCare?

A strong ESG-profile, and patented processes coupled with world class R&D with diversified pipelines including research programs on asthma, COVID-19 and gastro

Ticker: HBC
Last updated: 25.02.2021 16:09
Latest

8.76 NOK

Change

-0.16

Change (%)

-1.79

HBC 1
LATEST REPORT

Q4 2020 Report

Download our latest report, or view all quarterly and yearly reports in the archives.

16:9
NEXT UP

Financial calendar

Annual Report 2020
19.03.2021

Annual General Meeting
23.04.2021

Investor presentation

Download our latest investor presentation in PDF-format for a even deeper insight into our current ongoing business and future potential.

Download presentation

Contact investor relations

James Berger
James Berger
Head of Investor Relations & Strategy
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford Currie
Dr. Crawford Currie
Medical R&D & Investor Relations
+44 7968 195497 cc@hofsethbiocare.no